|Day's Range||0.472 - 0.490|
|52 Week Range||0.390 - 2.640|
|PE Ratio (TTM)||-1.35|
|Earnings Date||May 18, 2017 - May 19, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||11.52|
NEW YORK, NY / ACCESSWIRE / July 11, 2017 / Hemispherx Biopharma, Inc.'s shares saw a modest pop in share price yesterday after the company released an announcement about its Ampligen candidate that is ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
PHILADELPHIA, July 10, 2017-- Hemispherx Biopharma announced that 12 pancreatic patients are currently undergoing treatment with single-agent Ampligen immuno-oncology therapy in an Early Access Program ...